Early effects of rush immunotherapy with Dermatophagoides pteronyssinus in asthmatics
Апстракт
In this study we assessed the effects of Dermatophagoides pteronyssinus (Dpt) rush immunotherapy in comparison with placebo treatment in our asthmatic patients. Fourteen highly Dpt-susceptible adults were randomized in two groups (immunotherapy and placebo) and treated in single-blind manner. Patients were selected according to the recommendation of the immunotherapy position paper (1993). To minimize side effects we modified the protocol by adjusting allergen doses for each patient separately. Immunologic (total and Dpt-specific serum IgE and IgG antibodies/EIA, Pharmacia) and clinical parameters (spirometry, medication score and skin testing) were recorded before treatment, after 2 weeks, at the second month and after 4 months of immunotherapy onset. None of the patients had life-threatening side effects in the course of the treatment. The results obtained demonstrated significant influence of immunotherapy on Dpt-specific serum IgG synthesis (Kruskal Wallis test, p < 0.05) and on... the late phase skin reaction with Dpt (U-test, p < 0.05) at the end of the second month of immunotherapy onset. In the immunotherapy group, we also registered a negative correlation between concentrations of Dpt-specific serum IgE and IgG antibodies (p = -0.83; p < 0.05), at the end of the second month. In addition, diversities among patients, expressed by immunologic parameters, were related to the amount of delivered allergen. There were no significant differences between groups concerning medication score from opposite to better FEV1, PEFR and dPEFR results (Kruskal Wallis, p < 0.05) in the placebo group. In conclusion, Dpt-specific serum IgG concentration, immunologic score and late phase skin reactivity to allergen appeared to be the valid parameters of rush-immunotherapy achievement, while delivered allergen dose also seemed to be an influencing factor.
Кључне речи:
Asthma / Dermatophagoides / Immunotherapy / Pteronyssinus / RushИзвор:
Journal of Investigational Allergology and Clinical Immunology, 1997, 7, 6, 588-595Институција/група
TorlakTY - JOUR AU - Paranos, Svetlana AU - Petrović, Spomenka PY - 1997 UR - http://intor.torlakinstitut.com/handle/123456789/73 AB - In this study we assessed the effects of Dermatophagoides pteronyssinus (Dpt) rush immunotherapy in comparison with placebo treatment in our asthmatic patients. Fourteen highly Dpt-susceptible adults were randomized in two groups (immunotherapy and placebo) and treated in single-blind manner. Patients were selected according to the recommendation of the immunotherapy position paper (1993). To minimize side effects we modified the protocol by adjusting allergen doses for each patient separately. Immunologic (total and Dpt-specific serum IgE and IgG antibodies/EIA, Pharmacia) and clinical parameters (spirometry, medication score and skin testing) were recorded before treatment, after 2 weeks, at the second month and after 4 months of immunotherapy onset. None of the patients had life-threatening side effects in the course of the treatment. The results obtained demonstrated significant influence of immunotherapy on Dpt-specific serum IgG synthesis (Kruskal Wallis test, p < 0.05) and on the late phase skin reaction with Dpt (U-test, p < 0.05) at the end of the second month of immunotherapy onset. In the immunotherapy group, we also registered a negative correlation between concentrations of Dpt-specific serum IgE and IgG antibodies (p = -0.83; p < 0.05), at the end of the second month. In addition, diversities among patients, expressed by immunologic parameters, were related to the amount of delivered allergen. There were no significant differences between groups concerning medication score from opposite to better FEV1, PEFR and dPEFR results (Kruskal Wallis, p < 0.05) in the placebo group. In conclusion, Dpt-specific serum IgG concentration, immunologic score and late phase skin reactivity to allergen appeared to be the valid parameters of rush-immunotherapy achievement, while delivered allergen dose also seemed to be an influencing factor. T2 - Journal of Investigational Allergology and Clinical Immunology T1 - Early effects of rush immunotherapy with Dermatophagoides pteronyssinus in asthmatics EP - 595 IS - 6 SP - 588 VL - 7 UR - https://hdl.handle.net/21.15107/rcub_intor_73 ER -
@article{ author = "Paranos, Svetlana and Petrović, Spomenka", year = "1997", abstract = "In this study we assessed the effects of Dermatophagoides pteronyssinus (Dpt) rush immunotherapy in comparison with placebo treatment in our asthmatic patients. Fourteen highly Dpt-susceptible adults were randomized in two groups (immunotherapy and placebo) and treated in single-blind manner. Patients were selected according to the recommendation of the immunotherapy position paper (1993). To minimize side effects we modified the protocol by adjusting allergen doses for each patient separately. Immunologic (total and Dpt-specific serum IgE and IgG antibodies/EIA, Pharmacia) and clinical parameters (spirometry, medication score and skin testing) were recorded before treatment, after 2 weeks, at the second month and after 4 months of immunotherapy onset. None of the patients had life-threatening side effects in the course of the treatment. The results obtained demonstrated significant influence of immunotherapy on Dpt-specific serum IgG synthesis (Kruskal Wallis test, p < 0.05) and on the late phase skin reaction with Dpt (U-test, p < 0.05) at the end of the second month of immunotherapy onset. In the immunotherapy group, we also registered a negative correlation between concentrations of Dpt-specific serum IgE and IgG antibodies (p = -0.83; p < 0.05), at the end of the second month. In addition, diversities among patients, expressed by immunologic parameters, were related to the amount of delivered allergen. There were no significant differences between groups concerning medication score from opposite to better FEV1, PEFR and dPEFR results (Kruskal Wallis, p < 0.05) in the placebo group. In conclusion, Dpt-specific serum IgG concentration, immunologic score and late phase skin reactivity to allergen appeared to be the valid parameters of rush-immunotherapy achievement, while delivered allergen dose also seemed to be an influencing factor.", journal = "Journal of Investigational Allergology and Clinical Immunology", title = "Early effects of rush immunotherapy with Dermatophagoides pteronyssinus in asthmatics", pages = "595-588", number = "6", volume = "7", url = "https://hdl.handle.net/21.15107/rcub_intor_73" }
Paranos, S.,& Petrović, S.. (1997). Early effects of rush immunotherapy with Dermatophagoides pteronyssinus in asthmatics. in Journal of Investigational Allergology and Clinical Immunology, 7(6), 588-595. https://hdl.handle.net/21.15107/rcub_intor_73
Paranos S, Petrović S. Early effects of rush immunotherapy with Dermatophagoides pteronyssinus in asthmatics. in Journal of Investigational Allergology and Clinical Immunology. 1997;7(6):588-595. https://hdl.handle.net/21.15107/rcub_intor_73 .
Paranos, Svetlana, Petrović, Spomenka, "Early effects of rush immunotherapy with Dermatophagoides pteronyssinus in asthmatics" in Journal of Investigational Allergology and Clinical Immunology, 7, no. 6 (1997):588-595, https://hdl.handle.net/21.15107/rcub_intor_73 .